本帖最后由 老马 于 2012-1-13 21:20 编辑
0 F4 x$ Z, B3 n8 u" G$ ^8 S; a1 X5 c6 v0 w: k( R4 j9 |
爱必妥和阿瓦斯丁的比较
* `! m/ H# F3 c1 H# ^# v
( x; z8 l- ? O( R4 A$ X" Phttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/1 t2 s% B, h! ?1 o
. w( Q7 r0 Y! e$ H6 a
9 D6 L, X- G( B" t8 m2 Vhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/6 e6 O' h5 P# ] l
==================================================
& B2 M$ g- ~6 [) L1 T. uOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)! p0 f0 ~4 M* H, H2 U& w
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.2 @- C( Q2 j7 t& d" r/ Y5 N0 ^
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( w) @- X) x$ O, m5 h' g4 Q' a$ C/ P
|
显身卡
